View Older Stories
-
3 Reasons RBC Capital Thinks the Sarepta Therapeutics (SRPT) Patent Infringement Suit is not Meaningful
-
Pre-Open Stock Movers 06/18: (ALPN) (AEMD) (ELOX) Higher; (LPTX) (QUIK) (BIIB) Lower (more...)
-
Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
-
Sarepta Therapeutics (SRPT) PT Raised to $213 at RBC Capital
-
Sarepta Therapeutics (SRPT) May Have Sold Priority Review Voucher to Vifor - RBC
-
RBC Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) on Release of Full CRL Letter
-
Sarepta Therapeutics (SRPT) PT Lowered to $200 at RBC Capital
-
Sarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
-
Sarepta Therapeutics (SRPT) Defended at RBC
-
Sarepta Therapeutics (SRPT) Presenting Functional LGMD2E Data on 10/5 - RBC Capital
-
Sarepta Therapeutics (SRPT) PT Lowered to $204 at RBC Capital
-
Sarepta says adverse event report for DMD gene therapy erroneously submitted
-
FDA Adverse Event May Not Be 'Major Showstopper' for Sarepta Therapeutics (SRPT) Program - RBC
-
Sarepta Therapeutics (SRPT) PT Lowered to $218 at RBC Capital
-
Sarepta Therapeutics (SRPT) PT Raised to $220 at RBC Capital; Emrges as Clear Leader in DMD
-
Sarepta (SRPT) Has $3B +Additional Opportunity Beyond DMD/LGMD - RBC
-
Sarepta Therapeutics (SRPT) PT Lowered to $188 at RBC Capital
-
Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company
-
RBC Capital Weighs in Sarepta Therapeutics (SRPT) Confusion/Skepticism; Trims PT to $164
-
UPDATE: Sarepta Therapeutics (SRPT) Defended at RBC Capital
-
Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
-
Sarepta Therapeutics (SRPT) PT Lowered to $190 at RBC Capital
-
KOL Agrees that Sarepta (SRPT) High Microdystrophin Expression is Not Worrisome - RBC
-
Sarepta Therapeutics (SRPT) PT Raised to $200 at RBC Capital Following Management Meetings
-
Sarepta Therapeutics (SRPT) PT Lowered to $187 at RBC Capital
-
Sarepta Therapeutics (SRPT) PT Raised to $189 at RBC Capital
-
RBC Positive on Sarepta Therapeutics (SRPT) Into Tomorrow's R&D Day
-
RBC Positive on Biogen (BIIB) Karp Hire Amid Partnerships/M&A Potential
-
Sarepta Therapeutics (SRPT) PT Raised to $112 at RBC Capital
-
Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital
-
RBC Likes Set-Up for Sarepta Therapeutics (SRPT) Shares
-
Sarepta Therapeutics (SRPT) PT Raised to $91 at RBC Capital
-
RBC Capital Assumes Sarepta Therapeutics (SRPT) at Outperform
-
Sarepta Therapeutics (SRPT): Neurologists Survey Shows Strong Adoption of Exondys 51 - RBC
-
Sarepta Therapeutics (SRPT) PT Lowered to $60 at RBC Capital
-
Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital
-
KOLs Expect Sarepta (SRPT) EXONDYS 51 Reimbursement Issues to be Overcome, RBC Says; PT Trimmed to $98
-
Sarepta (SRPT) Gains as RBC Survey Suggests Docs Willing to Widely Use
-
RBC Recommends Buying Sarepta (SRPT) on Weakness Related to UnitedHealthcare Commercial Drug Policy
-
Trump presidency could prove a salve for pharma merger deals
-
RBC Affirms PTC Therapeutics (PTCT) at 'Sector Perform'; Doesn't See Translarna Appeal with Solid Chance
-
Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
-
Notable 52-Week Highs and Lows 9/28: (SRPT) (NVDA) (CLD) High; (FGP) (GBSN) Low
-
Pre-Open Stock Movers 09/28: (SEED) (AVXL) (ATHX) Higher; (GALT) (TPX) (SONC) Lower (more...)
-
Sarepta Therapeutic (SRPT) PT Raised Sharply to 'Street High' $108 at RBC Capital
-
RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target
-
FDA Rejection of Santhera Matters for Sarepta (SRPT), and Not in a Good Way - RBC Capital
-
Pre-Open Stock Movers 06/09: (ACUR) (CBK) (RADA) Higher; (RH) (INSM) (TMH) Lower (more...)
-
After-Hours Stock Movers 06/08: (RADA) (MSTX) (EAT) Higher; (RH) (INSM) (TMH) Lower (more...)
-
New Expanded Access Guidance Could Provide FDA a Way Out on Sarepta's (SRPT) Eteplirsen - RBC